INTCO Medical Honored with the 2024 Golden Information Disclosure Award

Recently, at the Listed Company Golden Bull Awards organized by China Securities Journal, INTCO Medical (Stock Code: 300677) was awarded the “Listed Company Golden Bull Award · 2024 Golden Information Disclosure Award.” This honor recognizes listed companies that demonstrate exemplary performance in information disclosure quality, investor relations management, and corporate governance, and reflects the capital market’s strong recognition of a company’s transparency and regulatory compliance.

INTCO Medical has consistently prioritized the establishment of a high-standard, transparent, and well-regulated information disclosure framework. Adhering to the principles of truthfulness, accuracy, completeness, timeliness, and fairness, the Company strictly complies with relevant securities laws and regulatory requirements. Through standardized periodic reporting, timely interim announcements, and proactive investor communication, INTCO Medical has continuously enhanced the quality and credibility of its disclosures, providing investors and market participants with clear, reliable, and decision-useful information.

From an institutional perspective, INTCO Medical has steadily optimized its internal information disclosure workflows and review mechanisms. By strengthening the professional capabilities of its board secretary and finance teams and embedding information disclosure into its corporate governance framework, the Company ensures the secure, timely, and comprehensive disclosure of operating performance, material events, and key strategic decisions. These systematic efforts have significantly improved disclosure efficiency and further strengthened market confidence in the Company’s operations.

The receipt of the 2024 Golden Information Disclosure Award represents not only authoritative recognition of INTCO Medical’s disclosure practices, but also a strong affirmation of its continuous progress in governance effectiveness, standardized operations, and investor relations management.

As a leading enterprise in China’s medical protective products industry, INTCO Medical continues to enhance its core business competitiveness while steadily advancing corporate governance and capital market performance. By maintaining a robust information disclosure system and actively promoting ESG practices, the Company has set a positive benchmark for the capital market. Looking ahead, INTCO Medical will remain committed to high-quality development, further elevating information disclosure standards, strengthening investor engagement, and deepening its social responsibility initiatives to support sustainable industry growth and the healthy development of the capital market.